{"result": "(\"entity\"<|>CISTATIONINA<|>ORGANIZATION<|>Cistationina is a biochemical compound involved in the metabolism of methionine and related amino acids.)\n##\n(\"entity\"<|>HOMOSERINA<|>ORGANIZATION<|>Homoserina is an amino acid that plays a role in the metabolic pathways of methionine.)\n##\n(\"entity\"<|>GLUTATIÓN<|>ORGANIZATION<|>Glutathione is a tripeptide that acts as an antioxidant and is involved in various metabolic processes.)\n##\n(\"entity\"<|>CISTINA<|>ORGANIZATION<|>Cystine is a dimer of cysteine and is involved in protein structure and metabolism.)\n##\n(\"entity\"<|>TAURINA<|>ORGANIZATION<|>Taurine is a sulfur-containing amino acid that is important for various biological functions.)\n##\n(\"entity\"<|>METIONINA<|>ORGANIZATION<|>Methionine is an essential amino acid that is a precursor for various important biomolecules.)\n##\n(\"entity\"<|>NEONATOS<|>PERSON<|>Neonates are newborn infants, particularly in the context of clinical manifestations related to metabolic disorders.)\n##\n(\"entity\"<|>NIÑOS<|>PERSON<|>Children are young human beings, often discussed in the context of clinical manifestations of diseases.)\n##\n(\"entity\"<|>ADULTOS<|>PERSON<|>Adults are mature human beings, referenced in the context of clinical manifestations of diseases.)\n##\n(\"entity\"<|>SÍNDROME DE MARFAN<|>EVENT<|>Marfan syndrome is a genetic disorder that affects connective tissue and is mentioned in relation to clinical manifestations.)\n##\n(\"entity\"<|>TRATAMIENTO<|>EVENT<|>Treatment refers to the medical care given to patients, particularly in the context of managing metabolic disorders.)\n##\n(\"relationship\"<|>CISTATIONINA<|>HOMOSERINA<|>Cistationina and Homoserina are both involved in the metabolism of methionine and related amino acids.<|>7)\n##\n(\"relationship\"<|>GLUTATIÓN<|>CISTINA<|>Glutathione and Cystine are both important in metabolic processes and antioxidant defense.<|>6)\n##\n(\"relationship\"<|>METIONINA<|>CISTINA<|>Methionine is a precursor to Cystine and is involved in its metabolism.<|>8)\n##\n(\"relationship\"<|>NEONATOS<|>SÍNDROME DE MARFAN<|>Neonates may exhibit clinical manifestations similar to those of Marfan syndrome.<|>5)\n##\n(\"relationship\"<|>NIÑOS<|>SÍNDROME DE MARFAN<|>Children may also show clinical manifestations related to Marfan syndrome.<|>5)\n##\n(\"relationship\"<|>ADULTOS<|>SÍNDROME DE MARFAN<|>Adults can experience clinical manifestations of Marfan syndrome as well.<|>5)\n##\n(\"relationship\"<|>TRATAMIENTO<|>NEONATOS<|>Treatment is necessary for neonates affected by metabolic disorders.<|>6)\n##\n(\"relationship\"<|>TRATAMIENTO<|>NIÑOS<|>Treatment is also required for children suffering from metabolic disorders.<|>6)\n##\n(\"relationship\"<|>TRATAMIENTO<|>ADULTOS<|>Adults require treatment for managing metabolic disorders.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: asa\n\n\n\n                                                                  Cistationina\n                                                                                                           α-cetobutirato\n                                                     Cistationinasa                  Homoserina\n                                    Glutatión                          Cys                        Cistina\n\n\n\n                                                                     Taurina\n\n\n\n                 Figura 3.    Metabolismo de la metionina. Cys: cisteína; Gly: glicina; Met: metionina;\n                 R: radical; THF: tetrahidrofolato. En azul, enzimas; en negrita, coenzimas.\n---\n 314      BLOQUE: PROTEÍNAS Y AMINOÁCIDOS\n\n\n\n4.2.    Manifestaciones clínicas                                          neonatos, 300-500 en niños y 500-1200 en adul-\n    La severidad de la enfermedad está relacionada con                    tos, siempre se reparte en tres dosis. Es preciso\nlos niveles de homocisteína y otros derivados disulfuro,                  recordar que dosis superiores 1000 mg/día pue-\nasí como con la precocidad del diagnóstico y comienzo                     den provocar neuropatía sensitiva y daño hepáti-\ndel tratamiento. Las manifestaciones son en parte simi-                   co. La respuesta, adecuada en los pacientes afec-\nlares al síndrome de Marfan e incluyen: osteoporosis,                     tos de la mitad de las mutaciones conocidas, se\naracnodactilia,      pectum excavatum           o  carinatum, pies        valora unas semanas más tarde de comenzar el\ncavos, genu valgum, escoliosis, luxación del cristalino,                  tratamiento o modificar las dosis.\ntrombosis intravascular y tromboembolismo e, incluso,                 Empleo      de    vías   metabólicas       alternativas     en  no\nretraso mental22, 23.                                                     respondedores a piridoxina o si no se hace bien la\n                                                                          dieta o como tratamiento adicional a esta. Pode-\n                                                                          mos disminuir la homocisteína, transformándola\n4.3.    Diagnóstico y control                                             en Met mediante la betaína-homocisteína metil-\n    Los niveles plasmáticos de Met pueden ser normales                    transferasa, administrando para ello betaína (tri-\n(5-40 μmol/l, 0,1-0,6 mg/dl) en el neonato afecto, por                    metiglicina) anhidra a dosis de 6-9 g/día (Farma-\nlo que muchas veces solo se diagnostica tras el inicio de                 cia    Hospitalaria:       Cystadane®)        repartida      en\nlos síntomas o mediante una concentración de homo-                        2-3 dosis o citrato de betaína (Farmacia Hospita-\ncisteína total en plasma o suero superior a 15 μmol/l. El                 laria) a dosis de 12-18 g/día. La betaína no afecta\ncontrol evolutivo se realiza mediante los niveles plasmá-                 al peso, composición corporal ni gasto energético\n                                                                          de los pacientes24.\nticos de Met y homocisteína (deseable: total < 50 μmol/l\ny libre <10 μmol/l)23.                                                También se puede utilizar la vía de la 5-metiltetrahi-\n4.4.    Tratamiento dietético-nutricional                           drofolato-homocisteína metiltransferasa, administran-\n                                                                    do vitamina B12 y folato (5 mg/día); el folato también\n    Es preciso limitar el aporte de PNAVB a 1,5-1,8 g/kg/día        es necesario administrarlo cuando empleamos piridoxi-\nen los niños, disminuyendo el aporte de alimentos ricos             na, por aumentar su demanda. Met puede aumentar\nen proteínas, pudiéndose dar algo más de legumbres y                hasta 1000 μmol/l, sin que se hayan encontrado efec-\ngelatina al contener menos Met. Se emplea un sistema de             tos adversos, pero se suele disminuir el tratamiento si\nintercambio similar al de la fenilcetonuria (como tabla 2,          se superan estos niveles.\naunque sin restricción de aspartamo), considerando que                En caso de que la homocistinuria esté ocasionada por\n1 g de proteína natural equivale a 20-25 mg de Met, to-             una alteración en el transporte intracelular de cobalami-\nlerándose una cantidad diaria muy variable entre 150 y              na, puede administrarse vitamina B12 a dosis altas, se-\n900 mg, pero muy constante en el mismo paciente. Pue-               gún respuesta, para mejorar el control metabólico.\nde ser necesario emplear suplementos con aa esenciales,\nenriquecido en cisteína (Cys) y micronutrientes y sin Met,          5.   Errores innatos del ciclo de la urea\nrepartido entre las comidas. Con este fin se emplean:\nHCU gel®, HCU express®, HCU cooler 15®, XMET Ana-\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}